Topics include the importance of chaperones, kinases, growth factors, inflammaging, mitochondrial dynamics, and oxidative stress. It presents targeted strategies to prevent cell death, reflecting ongoing pursuits in understanding and innovating treatments for neurodegenerative diseases. By offering therapeutic strategies to modulate RCD, this book not only shares knowledge but also provides hope for future advancements in combating these debilitating conditions.
Table of Contents
Chapter 1. Regulated Cell Death: Discovery, Features, and Implications for Neurodegenerative DiseasesChapter 2. Crosstalk Between Different Regulated Cell Death Mechanisms in Neurodegenerative Diseases
Chapter 3. Apoptosis in Neurodegenerative Disorders
Chapter 4. Necroptosis in Neurodegenerative Disorders
Chapter 5. Ferroptosis in Neurodegenerative Disorders
Chapter 6. Pyroptosis in Neurodegenerative Disorders
Chapter 7. Autophagy-Mediated Cell Death: Mechanisms and Implications in Neurodegenerative Disorders
Chapter 8. Potential targets for regulating cell death in neurodegenerative diseases
Chapter 9. Neuroprotective Role of Molecular Chaperones: Regulating Cell Survival and Death
Chapter 10. Navigating the Kinases Landscape: Impact on Regulated Cell Death mechanisms in Neurodegenerative disorders
Chapter 11: Growth Factors and regulated cell death in neurodegenerative disorders
Chapter 12. Regulated Cell Death and Inflammaging in Neurodegenerative Disorders
Chapter 13. Role of Oxidative Stress and Mitochondrial Dysfunction in Neurodegenerative Disorders
Chapter 14. Therapeutic Approaches Targeting Regulated Cell Death in Neurodegenerative Diseases: Current Understanding and Recent Advances in Combating Neuronal Loss
Authors
Heba Mohamed Mansour Central Administration of Biological, Innovative Products, and Clinical Studies (Bio-INN), Egyptian Drug Authority (EDA), Egypt.Heba Mohamed Mansour, Ph.D. is currently the Manager of the Innovative Products' Technical Evaluation Unit at the Central Administration of Biological, Innovative Products, and Clinical Studies (Bio-Inn) at the Egyptian Drug Authority (EDA). She is a topic leader in the ICH working group (EWG S13), specializing in non-clinical safety assessments of oligonucleotide-based therapeutics (ONTs). Heba received a PhD degree in pharmacology and toxicology from the Faculty of Pharmacy, Cairo University in 2024. Her expertise encompasses a profound understanding of diverse cell death modalities in neurodegeneration and the exploration of potential drug repositioning strategies involving anti-cancer kinase inhibitors for neurodegenerative disorders. Her contributions extend to numerous research articles, prestigious international journal publications, book chapters, books, and comprehensive review articles, solidifying her interest in the field.
Aiman Saad El-Khatib Egyptian Drug Authority (EDA) and Professor of Pharmacology and Toxicology in the Faculty of Pharmacy, Cairo University, Egypt.Aiman Saad El-Khatib, Ph.D. is currently the Vice President of the Egyptian Drug Authority. He is a Professor of Pharmacology and Toxicology in the Faculty of Pharmacy, Cairo University since May 2002. He held several leadership positions in Cairo University including Vice President for Graduate Studies and Research Affairs, Dean of Faculty of Pharmacy, Vice Dean for Education and Students Affairs as well as Vice Dean for Community Service and Environment Development. Additionally, he held the post of Assistant Minister of Health and Population for Pharmaceutical Affairs. His primary research area of interest is the investigation of the pharmacological properties of various drugs, including natural products on the gastrointestinal tract, cardiovascular and central nervous systems. He published numerous articles in international journals. His awards include Cairo University Scientific Research Fosterage in the field of Theoretical and Applied Biological Sciences in 2004 and, Silver and Gold Medal of Merit from Egyptian Syndicate of Pharmacists in 2004 and 2005.
